RoB 2: a revised tool for assessing risk of bias in randomised trials

Assessment of risk of bias is regarded as an essential component of a systematic review on the effects of an intervention. The most commonly used tool for randomised trials is the Cochrane risk-of-bias tool. We updated the tool to respond to developments in understanding how bias arises in randomised trials, and to address user feedback on and limitations of the original tool.

[1]  Isabelle Boutron,et al.  Impact of single centre status on estimates of intervention effects in trials with continuous outcomes: meta-epidemiological study , 2012, BMJ : British Medical Journal.

[2]  Julian P. T. Higgins,et al.  Rethinking the assessment of risk of bias due to selective reporting: a cross-sectional study , 2016, Systematic Reviews.

[3]  Jelena Savović,et al.  Empirical Evidence of Study Design Biases in Randomized Trials: Systematic Review of Meta-Epidemiological Studies , 2016, PloS one.

[4]  Sally Hopewell,et al.  Incorporation of assessments of risk of bias of primary studies in systematic reviews of randomised trials: a cross-sectional study , 2013, BMJ Open.

[5]  G. Guyatt,et al.  GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. , 2011, Journal of clinical epidemiology.

[6]  David Moher,et al.  Evolution of poor reporting and inadequate methods over time in 20 920 randomised controlled trials included in Cochrane reviews: research on research study , 2017, British Medical Journal.

[7]  Sergio Sismondo,et al.  Industry sponsorship and research outcome. , 2012, The Cochrane database of systematic reviews.

[8]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[9]  Lisa Hartling,et al.  Testing the risk of bias tool showed low reliability between individual reviewers and across consensus assessments of reviewer pairs. , 2013, Journal of clinical epidemiology.

[10]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[11]  Susan Mallett,et al.  Circulating MicroRNAs as a Novel Class of Diagnostic Biomarkers in Gastrointestinal Tumors Detection: A Meta-Analysis Based on 42 Articles , 2014, PloS one.

[12]  C. Bias.  The Cochrane Collaboration's tool for assessing risk of bias in randomised trials , 2011 .

[13]  Miguel A Hernán,et al.  Adherence adjustment in the Coronary Drug Project: A call for better per-protocol effect estimates in randomized trials , 2016, Clinical trials.

[14]  James M Robins,et al.  Per-Protocol Analyses of Pragmatic Trials. , 2017, The New England journal of medicine.

[15]  Mark Petticrew,et al.  How do systematic reviews incorporate risk of bias assessments into the synthesis of evidence? A methodological study , 2014, Journal of Epidemiology & Community Health.

[16]  Julian P T Higgins,et al.  Biases in Randomized Trials: A Conversation Between Trialists and Epidemiologists. , 2017, Epidemiology.

[17]  M. Hernán,et al.  ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions , 2016, British Medical Journal.

[18]  G. Guyatt,et al.  Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis , 2002, BMJ : British Medical Journal.

[19]  David Moher,et al.  Evaluation of the Cochrane Collaboration’s tool for assessing the risk of bias in randomized trials: focus groups, online survey, proposed recommendations and their implementation , 2014, Systematic Reviews.

[20]  Isabelle Boutron,et al.  Evaluation of the Cochrane tool for assessing risk of bias in randomized clinical trials: overview of published comments and analysis of user practice in Cochrane and non-Cochrane reviews , 2016, Systematic Reviews.

[21]  M. Hernán,et al.  Beyond the intention-to-treat in comparative effectiveness research , 2012, Clinical trials.

[22]  Haitao Chu,et al.  The per-protocol effect of immediate versus deferred antiretroviral therapy initiation , 2016, AIDS.